About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main objectives are to improve the diagnosis of immunodeficiencies and autoimmune diseases, addressing also their heterogeneity and mechanisms in close collaboration with the pediatrics, thyroid and systemic disease groups, being internationally recognized in both areas. The group participates in numerous research projects at the Vall d'Hebron Barcelona Hospital Campus that use immunological tests developed for specific projects led by the kidney transplantation, intensive care medicine, internal medicine, allergy and rheumatology groups. During the COVID pandemic the group made contributions in improving the immunogenetic and immunological risk profiles and in the evaluation of the immune response to vaccination and natural infection, collaborating with national and international networks. The group has also generated a biobank of more than 8.000 samples from patients with COVID-19 that have been incorporated into the VHIR biobank.
The group works as a coordinator of the "Focis" Center of Excellence (Federation of Clinical Immunology Societies) of Barcelona.
PMID: 38123718 Journal: Nature Metabolism Year: 2023 Reference: Nat Metab. 2023 Dec;5(12):2094-2110. doi: 10.1038/s42255-023-00937-1. Epub 2023 Dec 20. Impact factor: Publication type: Paper in international publication Authors: Alvarez-Sierra, Daniel; Choudhury, Feroza K; Hankeova, Simona; Kamath, Binita M; Lai, Zijuan; Mosteiro, Lluc; Nguyen, Thi Thu Thao; Piskol, Robert; Pujol-Borrell, Ricardo; Reichelt, Mike et al. DOI: 10.1038/s42255-023-00937-1
PMID: 35403441 Journal: THYROID Year: 2022 Reference: Thyroid. 2022 Jun;32(6):682-693. doi: 10.1089/thy.2021.0694. Epub 2022 May 25. Impact factor: 6.568 Publication type: Paper in international publication Authors: Zafon, Carles, Alvarez de la Sierra, Daniel, Marin-Sanchez, Ana, Gomez-Brey, Aroa, Bello, Irene, Caubet, Enric, Moreno-Llorente, Pablo, Petit, Anna, Pujol-Borrell, Ricardo, Gonzalez, Oscar et al. DOI: 10.1089/thy.2021.0694
PMID: 35351135 Journal: BMC Medicine Year: 2022 Reference: BMC Med. 2022 Mar 29;20(1):129. doi: 10.1186/s12916-022-02345-w. Impact factor: 8.775 Publication type: Paper in international publication Authors: Gallo, Monica Martinez, Arrese-Munoz, Iria, Gine, Anna, Diaz-Troyano, Noelia, Gabriel-Medina, Pablo, Riveiro-Barciela, Mar, Labrador-Horrillo, Moises, Martinez-Valle, Fernando, Montalva, Adrian Sanchez, Hernandez-Gonzalez, Manuel et al. DOI: 10.1186/s12916-022-02345-w
PMID: 35177626 Journal: Nature Communications Year: 2022 Reference: Nat Commun. 2022 Feb 17;13(1):915. doi: 10.1038/s41467-022-28621-0. Impact factor: 14.919 Publication type: Paper in international publication Authors: Kraker, Geoffrey, Jaimes, Maria C, Van Bockstael, Sebastiaan, Hernandez-Gonzalez, Manuel, Rokx, Casper, Rijnders, Bart J A, Pujol-Borrell, Ricardo, Katsikis, Peter D, van Wees, Tamara, Laport, Danique A et al. DOI: 10.1038/s41467-022-28621-0
PMID: 34844263 Journal: Blood Advances Year: 2022 Reference: Blood Adv. 2022 Feb 8;6(3):774-784. doi: 10.1182/bloodadvances.2021006101. Impact factor: 6.799 Publication type: Paper in international publication Authors: Orfao, Alberto, Jimenez, Moraima, Roldan, Elisa, Fernandez-Naval, Candela, Villacampa, Guillermo, Martinez-Gallo, Monica, Medina-Gil, Daniel, Peralta-Garzon, Soraya, Pujadas, Gemma, Hernandez, Cristina et al. DOI: 10.1182/bloodadvances.2021006101
PMID: 31865540 Journal: INTERNATIONAL JOURNAL OF HEMATOLOGY Year: 2020 Reference: Int J Hematol. 2020 Mar;111(3):440-450. doi: 10.1007/s12185-019-02796-7. Epub 2019 Dec 21. Impact factor: 2.245 Publication type: Paper in international publication Authors: Rincon, Rafael, Vinas-Gimenez, Laura, Donadeu, Laura, Alsina, Laia, Catala, Albert, Colobran, Roger, de la Cruz, Xavier, Sayos, Joan, Martinez-Gallo, Monica, Esteve-Sole, Ana et al. DOI: 10.1007/s12185-019-02796-7
PMID: 31701864 Journal: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Year: 2020 Reference: Am J Trop Med Hyg. 2020 Jan;102(1):159-163. doi: 10.4269/ajtmh.19-0550. Impact factor: 2.126 Publication type: Paper in international publication Authors: Molina, Israel, Silgado, Aroa, Moure, Zaira, Bosch-Nicolau, Pau, Salvador, Fernando, Sanchez-Montalva, Adrian, Martinez-Gallo, Monica, Sulleiro, Elena, Franco-Jarava, Clara, Sao Aviles, Augusto et al. DOI: 10.4269/ajtmh.19-0550
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
A study from the Vall d’Hebron Campus demonstrates that the Ex Vivo C5b-9 deposition test is useful for monitoring the activity of the complement system (CS) in patients with aHUS or transplant-associated TMA.
The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.
